The identification of heavy metals by sensing technologies is a crucial area of study since these metals are present in the environment and are hazardous. The in-depth analyses of the probes' structures and sensing capabilities improve our understanding of how to design and develop probes for the same metal in the future. The third most common metal ion and trace element, copper (Cu2+), is essential to all living things and is involved in several activities. However, different diseases are caused by excess or deficiency of Cu2+ ions, depending on what the cell requires. For all of these reasons, optical sensors have concentrated on quick, highly sensitive, and selective real-time detection of Cu2+ ions. Fluorescence in the refractive index-adsorption from the interactions between light and matter can be measured using optical sensors. Furthermore, due to their strong advantages which include real-time detection, simplicity and naked eye recognition, low cost, high specificity against analytes, quick reaction, and the requirement for less complex equipment during analysis they have attracted a lot of attention in recent years. In this review, we covered many fluoro and chemosensors for the detection of copper, along with their sensing parameters in various mediums and thorough structural analyses. This review also covers the extraction of copper from the aqueous medium. The use of membrane processes, adsorption, and electrocoagulation is examined, and the difficulties associated with their application have been presented.
{"title":"An Overview of Optical Sensing of Copper and its Removal by Different\u0000Techniques","authors":"Srishti Dutta, Dishen Kumar Banjara, Abhilash Pandey, Vansikha Sharma, Devanand Sahu, Niraj Kumari, G. Patra","doi":"10.2174/012210299x281975240709092821","DOIUrl":"https://doi.org/10.2174/012210299x281975240709092821","url":null,"abstract":"\u0000\u0000The identification of heavy metals by sensing technologies is a crucial area of study since these metals are present in the environment and are\u0000hazardous. The in-depth analyses of the probes' structures and sensing capabilities improve our understanding of how to design and develop probes\u0000for the same metal in the future. The third most common metal ion and trace element, copper (Cu2+), is essential to all living things and is involved\u0000in several activities. However, different diseases are caused by excess or deficiency of Cu2+ ions, depending on what the cell requires. For all of\u0000these reasons, optical sensors have concentrated on quick, highly sensitive, and selective real-time detection of Cu2+ ions. Fluorescence in the\u0000refractive index-adsorption from the interactions between light and matter can be measured using optical sensors. Furthermore, due to their strong\u0000advantages which include real-time detection, simplicity and naked eye recognition, low cost, high specificity against analytes, quick reaction, and\u0000the requirement for less complex equipment during analysis they have attracted a lot of attention in recent years. In this review, we covered many\u0000fluoro and chemosensors for the detection of copper, along with their sensing parameters in various mediums and thorough structural analyses.\u0000This review also covers the extraction of copper from the aqueous medium. The use of membrane processes, adsorption, and electrocoagulation is\u0000examined, and the difficulties associated with their application have been presented.\u0000","PeriodicalId":505533,"journal":{"name":"Current Indian Science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141653797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-11DOI: 10.2174/012210299x313252240521111358
Aditya Narayan, Arsh Chanana, Oma Shanker, Yukta R. Kulkarni, Pooja Gupta, Akhilesh Patel, Ujwal Havelikar, Ravindra Pal Singh, H. Chawra
One of the most popular sectors in the tech and healthcare industries right now is artificial intelligence. In the search and development of new drugs, artificial intelligence is essential. Drug design using computer-assisted design (CADD) has supplanted the traditional approach. Artificial intelligence is assisting businesses in the development of new drugs in a faster, more affordable, and more efficient manner, saving money and manpower in the process of creating new drug molecules to treat any disease. Quantitative structure-activity relationship (QSAR) analysis, activity scoring, in silico testing, biomarker development, and mode of action identification are all aided by artificial intelligence. It is revolutionizing these sectors by swiftly identifying potential drug candidates, efficiently conducting clinical trials, and customizing patient care. AI optimizes drug manufacturing processes, augments safety monitoring, and streamlines market analysis. In clinical trials, AI streamlines patient recruitment and ensures more precise trial designs, leading to faster and more efficient research. AI empowers personalized medicine by tailoring treatment plans and drug dosages to individual patient characteristics. AI also optimizes pharmaceutical manufacturing processes, amplifies safety monitoring by analyzing real-time data for adverse events, and supports market analysis and sales strategies. AI in the pharmaceutical industry is a multifaceted tool. Artificial Intelligence (AI) has the potential to streamline complex pharmaceutical regulatory matters. Regulatory processes like audits and dossier completion can be automated with AI tools.
{"title":"Role of Artificial Intelligence in Pharmaceutical Drug Development","authors":"Aditya Narayan, Arsh Chanana, Oma Shanker, Yukta R. Kulkarni, Pooja Gupta, Akhilesh Patel, Ujwal Havelikar, Ravindra Pal Singh, H. Chawra","doi":"10.2174/012210299x313252240521111358","DOIUrl":"https://doi.org/10.2174/012210299x313252240521111358","url":null,"abstract":"\u0000\u0000One of the most popular sectors in the tech and healthcare industries right now is artificial intelligence. In the search and development of new\u0000drugs, artificial intelligence is essential. Drug design using computer-assisted design (CADD) has supplanted the traditional approach. Artificial\u0000intelligence is assisting businesses in the development of new drugs in a faster, more affordable, and more efficient manner, saving money and\u0000manpower in the process of creating new drug molecules to treat any disease. Quantitative structure-activity relationship (QSAR) analysis, activity\u0000scoring, in silico testing, biomarker development, and mode of action identification are all aided by artificial intelligence. It is revolutionizing these\u0000sectors by swiftly identifying potential drug candidates, efficiently conducting clinical trials, and customizing patient care. AI optimizes drug\u0000manufacturing processes, augments safety monitoring, and streamlines market analysis. In clinical trials, AI streamlines patient recruitment and\u0000ensures more precise trial designs, leading to faster and more efficient research. AI empowers personalized medicine by tailoring treatment plans\u0000and drug dosages to individual patient characteristics. AI also optimizes pharmaceutical manufacturing processes, amplifies safety monitoring by\u0000analyzing real-time data for adverse events, and supports market analysis and sales strategies. AI in the pharmaceutical industry is a multifaceted\u0000tool. Artificial Intelligence (AI) has the potential to streamline complex pharmaceutical regulatory matters. Regulatory processes like audits and\u0000dossier completion can be automated with AI tools.\u0000","PeriodicalId":505533,"journal":{"name":"Current Indian Science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141656338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aims to explore the binding interactions between synthesized 3,3’-Disubstituted Oxindoles and the HCK enzyme, with the specific goal of discovering potential anticancer agents. Cancer presents an ongoing global health challenge, necessitating the exploration of innovative therapeutic approaches. Isatin derivatives and pyridine compounds hold great promise for the development of anticancer drugs due to their wide-ranging biological activities. Moreover, HCK plays a significant role in chemotherapy resistance and reduced drug efficacy in clinical settings, highlighting its importance in the intricate network of cancer pathophysiology. There is an urgent need for targeted interventions to regulate HCK activity and enhance cancer treatment outcomes. In our study, we ensured meticulous optimization of protein and ligand preparation to guarantee accurate docking simulations. We conducted molecular docking analyses using the state-of-the-art Glide module and assessed ADME properties using the Schrödinger suite's QikProp tool. Through molecular docking, compounds 3c and 3e have emerged as promising anticancer agents with low docking scores against Tyrosine Kinase. Further ADME analysis has provided valuable insights into the compounds' in-silico behaviour, while computed dipole moments have enhanced our understanding of their physicochemical characteristics In this study, we explored how the synthesized compounds bind within the HCK active site, indicating potential anticancer properties. Through in silico docking, we identified compounds 3c and 3e as possible anticancer agents, with the lowest docking scores of -7.621 and -7.602 kcal/mol against Tyrosine Kinase. These findings emphasize the importance of computational approaches in drug discovery and offer valuable insights for future research and development efforts.
{"title":"Evaluation of 3, 3’-Disubstituted Oxindoles Derivatives as a Potential Anti-\u0000Cancer Tyrosine Kinase Inhibitors-Molecular Docking and ADME Studies","authors":"Sukhmeet Kaur, Kirandeep Kaur, Jasneet Kaur, Raghav Mahajan, Jyotisina, Kulwinder Kaur","doi":"10.2174/012210299x310595240626104426","DOIUrl":"https://doi.org/10.2174/012210299x310595240626104426","url":null,"abstract":"\u0000\u0000This study aims to explore the binding interactions between synthesized 3,3’-Disubstituted Oxindoles and the HCK enzyme, with the specific goal\u0000of discovering potential anticancer agents.\u0000\u0000\u0000\u0000Cancer presents an ongoing global health challenge, necessitating the exploration of innovative therapeutic approaches. Isatin derivatives and\u0000pyridine compounds hold great promise for the development of anticancer drugs due to their wide-ranging biological activities. Moreover, HCK\u0000plays a significant role in chemotherapy resistance and reduced drug efficacy in clinical settings, highlighting its importance in the intricate\u0000network of cancer pathophysiology. There is an urgent need for targeted interventions to regulate HCK activity and enhance cancer treatment\u0000outcomes.\u0000\u0000\u0000\u0000In our study, we ensured meticulous optimization of protein and ligand preparation to guarantee accurate docking simulations. We conducted\u0000molecular docking analyses using the state-of-the-art Glide module and assessed ADME properties using the Schrödinger suite's QikProp tool.\u0000\u0000\u0000\u0000Through molecular docking, compounds 3c and 3e have emerged as promising anticancer agents with low docking scores against Tyrosine Kinase.\u0000Further ADME analysis has provided valuable insights into the compounds' in-silico behaviour, while computed dipole moments have enhanced\u0000our understanding of their physicochemical characteristics\u0000\u0000\u0000\u0000In this study, we explored how the synthesized compounds bind within the HCK active site, indicating potential anticancer properties. Through in\u0000silico docking, we identified compounds 3c and 3e as possible anticancer agents, with the lowest docking scores of -7.621 and -7.602 kcal/mol\u0000against Tyrosine Kinase. These findings emphasize the importance of computational approaches in drug discovery and offer valuable insights for\u0000future research and development efforts.\u0000","PeriodicalId":505533,"journal":{"name":"Current Indian Science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141682927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The unique physicochemical properties, low cost, low toxicity, and size- and shape-dependent magnetic properties of the ferrite-based nanoparticles make them an indispensable choice of material for various applications, including catalysis. The objective of this review is to summarize the results of the most widely used ferrite nanoparticles such as NiFe2O4, CuFe2O4, CoFe2O4, ZnFe2O4, and MnFe2O4 as catalysts in organic reactions such as C–X (X = N, O, and S) coupling, oxidation, and N-heterocycles formation reactions. This review includes a well-summarized compilation of the most widely used nanostructured ferrites such as NiFe2O4, CuFe2O4, CoFe2O4, ZnFe2O4, and MnFe2O4 as heterogeneous catalysts in selected organic reactions such as C–X (X = N, O, and S) coupling, oxidation, and N-heterocycles formation reactions. The nanostructured magnetic ferrite catalysts are reliable and extremely effective and facilitate the quick separation of catalysts, making the process sustainable. The presentation of the review has been proposed anticipating new perspectives and insight in the field of catalysis and investigate further development of novel ferrite materials on an industrial scale for practical applications.
{"title":"Recent Developments in the Use of Spinel Ferrite Nanoparticles as Catalysts in\u0000Organic Reactions","authors":"Babul Kalita, Saddam Iraqui, Gariyasee Dutta, Md. Harunar Rashid","doi":"10.2174/012210299x312557240625064143","DOIUrl":"https://doi.org/10.2174/012210299x312557240625064143","url":null,"abstract":"\u0000\u0000The unique physicochemical properties, low cost, low toxicity, and size- and shape-dependent magnetic properties of the ferrite-based\u0000nanoparticles make them an indispensable choice of material for various applications, including catalysis.\u0000\u0000The objective of this review is to summarize the results of the most widely used ferrite nanoparticles such as NiFe2O4, CuFe2O4, CoFe2O4, ZnFe2O4,\u0000and MnFe2O4 as catalysts in organic reactions such as C–X (X = N, O, and S) coupling, oxidation, and N-heterocycles formation reactions.\u0000\u0000This review includes a well-summarized compilation of the most widely used nanostructured ferrites such as NiFe2O4, CuFe2O4, CoFe2O4, ZnFe2O4,\u0000and MnFe2O4 as heterogeneous catalysts in selected organic reactions such as C–X (X = N, O, and S) coupling, oxidation, and N-heterocycles\u0000formation reactions. The nanostructured magnetic ferrite catalysts are reliable and extremely effective and facilitate the quick separation of\u0000catalysts, making the process sustainable.\u0000\u0000The presentation of the review has been proposed anticipating new perspectives and insight in the field of catalysis and investigate further\u0000development of novel ferrite materials on an industrial scale for practical applications.\u0000","PeriodicalId":505533,"journal":{"name":"Current Indian Science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141681057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-07DOI: 10.2174/012210299x258665231205115939
Manvi Sharma, Prince P. George, Ranjeet Kumar, Amit Sharma
Tezepelumab is a first-in-class human IgG2λ monoclonal antibody used to treat severe, uncontrolled asthma. Tezepelumab acts by hindering the action of thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine that triggers an immunological response by binding to TSLP and thereby preventing its binding with the TSLP receptor complex. TSLP has a critical role in Th2 immunity and plays an important role in the pathogenesis of asthma because it stimulates the production of Th2-associated inflammatory mediators, such as interleukin-4, interleukin-5, interleukin-9, and interleukin-13. It is the first biologic with no phenotypic or biomarker restrictions that has been approved for use in severe asthma. Tezepelumab is indicated in severe, uncontrolled asthma patients due to its safety, tolerability, and efficacy. Adults with severe, uncontrolled asthma experienced considerably lower annualised asthma exacerbation rates (AAERs) when administered with tezepelumab compared to a placebo. These preliminary results indicated that the TSLP-induced release of T2 inflammatory mediators may be reduced, and the sustained inhibition was maintained over a 52-week treatment period. In this review, we have summarised various phase III clinical trials and the mechanism of action of tezepelumab in severe, uncontrolled asthma.
{"title":"New Drug for Management of Severe Uncontrolled Asthma: Tezepelumab","authors":"Manvi Sharma, Prince P. George, Ranjeet Kumar, Amit Sharma","doi":"10.2174/012210299x258665231205115939","DOIUrl":"https://doi.org/10.2174/012210299x258665231205115939","url":null,"abstract":"\u0000\u0000Tezepelumab is a first-in-class human IgG2λ monoclonal antibody used to treat severe, uncontrolled asthma. Tezepelumab acts by hindering the\u0000action of thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine that triggers an immunological response by binding to TSLP and\u0000thereby preventing its binding with the TSLP receptor complex. TSLP has a critical role in Th2 immunity and plays an important role in the\u0000pathogenesis of asthma because it stimulates the production of Th2-associated inflammatory mediators, such as interleukin-4, interleukin-5,\u0000interleukin-9, and interleukin-13. It is the first biologic with no phenotypic or biomarker restrictions that has been approved for use in severe\u0000asthma. Tezepelumab is indicated in severe, uncontrolled asthma patients due to its safety, tolerability, and efficacy. Adults with severe,\u0000uncontrolled asthma experienced considerably lower annualised asthma exacerbation rates (AAERs) when administered with tezepelumab\u0000compared to a placebo. These preliminary results indicated that the TSLP-induced release of T2 inflammatory mediators may be reduced, and the\u0000sustained inhibition was maintained over a 52-week treatment period. In this review, we have summarised various phase III clinical trials and the\u0000mechanism of action of tezepelumab in severe, uncontrolled asthma.\u0000","PeriodicalId":505533,"journal":{"name":"Current Indian Science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140259684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-07DOI: 10.2174/012210299x265033240116113623
Ganesh S. Mhaske, Sanket R. Thorat, Varun S. Pawar, Ravindra S. Pawar, S. R. Jambhulkar, Omkar A. Ghumre
The creation and development of novel chemical entities is made possible by numerous computer-aided drug design techniques. The ability to visualize the ligand-target interaction and forecast the important holding pocket locations and affinities of ligands to their intended macromolecules is made possible by pharmacophore-based drug design and understanding in-silico methodologies. The aim of the current investigation was to find novel 2-chloroquinoline-3-carboxamide derivatives that target the Ephrin B4 (EPHB4) receptor to treat cancer. Chem Axon Marvin Sketch 5.11.5 was used to create derivatives of 2-chloroquinoline-3-carboxamide. The physicochemical characteristics of compounds as well as their toxicity were predicted using SwissADME& the admet SAR online software’s. Molecular docking technology was used to examine the ligand-receptor interactions of 2-chloroquinoline-3-carboxamide derivatives with the target receptor (PDB- 6FNM) using a variety of software’s, including Autodock1.1.2,Procheck, ProtParam tool, Biovia Discovery Studio Visualizer v20.1.0.19295, MGL Tools 1.5.6, PyMOL, and were all included. All developed compounds were determined to be orally bioavailable, less toxic, and have acceptable pharmacokinetic properties according to in silico studies. In comparison to the traditional medication Erdafitnib, all new compounds displayed higher docking scores. The increase in binding energy and the number of H-bonds created by novel derivatives with interactions at distances below 3.40A provide a helpful starting point for formulating and synthesizing compounds that are most suitable for additional research. The application of the 2- chloroquinoline-3-carboxamide moiety as a potential new cancer treatment candidate is supported by its pharmacokinetics &toxicological profile, which may aid medicinal chemists in conducting more in-depth in vitro, in vivo chemical and pharmacological studies.
许多计算机辅助药物设计技术使新型化学实体的创造和开发成为可能。基于药理的药物设计和理解力的硅学方法使配体与靶点相互作用的可视化以及预测配体与目标大分子的重要持袋位置和亲和力的能力成为可能。使用 SwissADME 和 admet SAR 在线软件预测了化合物的理化特性及其毒性。利用分子对接技术研究了 2-氯喹啉-3-甲酰胺衍生物与目标受体（PDB- 6FNM）的配体-受体相互作用，使用的软件包括 Autodock1.1.所有开发的化合物都具有口服生物利用度高、毒性低和可接受的药代动力学特性。与传统药物 Erdafitnib 相比，所有新化合物都显示出更高的对接得分。新型衍生物的结合能和相互作用距离低于 3.40A 时产生的 H 键数量的增加，为配制和合成最适合进一步研究的化合物提供了一个有益的起点。2-氯喹啉-3-甲酰胺分子作为一种潜在的癌症治疗新候选化合物的应用得到了其药代动力学和毒理学特征的支持，这可能有助于药物化学家进行更深入的体外、体内化学和药理学研究。
{"title":"Computational Molecular Docking and In-Silico, ADMET Prediction Studies of\u0000Quinoline Derivatives as EPHB4 Inhibitor","authors":"Ganesh S. Mhaske, Sanket R. Thorat, Varun S. Pawar, Ravindra S. Pawar, S. R. Jambhulkar, Omkar A. Ghumre","doi":"10.2174/012210299x265033240116113623","DOIUrl":"https://doi.org/10.2174/012210299x265033240116113623","url":null,"abstract":"\u0000\u0000The creation and development of novel chemical entities is made possible by numerous computer-aided drug design techniques. The ability to\u0000visualize the ligand-target interaction and forecast the important holding pocket locations and affinities of ligands to their intended macromolecules\u0000is made possible by pharmacophore-based drug design and understanding in-silico methodologies.\u0000\u0000\u0000\u0000The aim of the current investigation was to find novel 2-chloroquinoline-3-carboxamide derivatives that target the Ephrin B4 (EPHB4) receptor to\u0000treat cancer.\u0000\u0000\u0000\u0000Chem Axon Marvin Sketch 5.11.5 was used to create derivatives of 2-chloroquinoline-3-carboxamide. The physicochemical characteristics of\u0000compounds as well as their toxicity were predicted using SwissADME& the admet SAR online software’s. Molecular docking technology was\u0000used to examine the ligand-receptor interactions of 2-chloroquinoline-3-carboxamide derivatives with the target receptor (PDB- 6FNM) using a\u0000variety of software’s, including Autodock1.1.2,Procheck, ProtParam tool, Biovia Discovery Studio Visualizer v20.1.0.19295, MGL Tools 1.5.6,\u0000PyMOL, and were all included.\u0000\u0000\u0000\u0000All developed compounds were determined to be orally bioavailable, less toxic, and have acceptable pharmacokinetic properties according to in\u0000silico studies. In comparison to the traditional medication Erdafitnib, all new compounds displayed higher docking scores.\u0000\u0000\u0000\u0000The increase in binding energy and the number of H-bonds created by novel derivatives with interactions at distances below 3.40A provide a\u0000helpful starting point for formulating and synthesizing compounds that are most suitable for additional research. The application of the 2-\u0000chloroquinoline-3-carboxamide moiety as a potential new cancer treatment candidate is supported by its pharmacokinetics &toxicological profile,\u0000which may aid medicinal chemists in conducting more in-depth in vitro, in vivo chemical and pharmacological studies.\u0000","PeriodicalId":505533,"journal":{"name":"Current Indian Science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140258734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：